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ABSTRACT 
To ascertain whether prostaglandins (PG) may play a role in the 
secretion of glucagon and in an attempt to elucidate the conflicting 
observations on the effects of PG on insulin release, the isolated in- 
tact rat 
5 
ancreas was perfused with solutions containing 1.1 x 10sg to 
1.8 x lo- M PGE2. In the presence of 5.6 mM glucose significant in- 
crements in portal venous effluent levels of glucagon and insulin were 
observed in response to minimal concentrations of 2.8 x 10-8 and 1.4 x 
lo-%l PGE2, respectively; a dose-response relationship was evident for 
both hormones at higher concentrations of PGE2. When administered 
over 60 seconds, 1.4 x lo-6M PGE2 resulted in a significant increase 
in glucagon levels within 24 seconds and in insulin within 48 seconds. 
Ten-minute perfusions of 1.4 x 10m6M PGE2 elicited biphasic release of 
both islet hormones; Phase I glucagon release preceded that of insulin. 
Both phases of the biphasic glucagon and insulin release which occur- 
red in response to 15-minute perfusions of 10 mM arginine were aug- 
mented by PGE2. 
cagon and 
These observations indicate that PGE2 can evoke glu- 
insulin release at concentrations close to those observed by 
others in the extracts of rat pancreas. We conclude that PG may be 
involved in the regulation of secretion of glucagon and insulin and 
may mediate and/or modify the pancreatic islet hormone response to 
other secretagogues. 
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INTRODUCTION 
Administered or endogenous prostaglandins (PG) have been shown to 
affect the release of hormones from various endocrine glands (1). Ev- 
idence has been presented that PG produced in situ within the endo- -- 
crine glands may mediate the effects of certain secretagogues (2). 
The reports on the effects of PG upon insulin release have been con- 
tradictory. Stimulation of insulin secretion or increases in plasma 
levels of insulin in response to PGEl have been observed in vitro and -- 
in vivo (3-5). -- Other investigators could not show any effect of PG 
on insulin release in vitro or in vivo (6-11). On the other hand -- -- 
Robertson et al. reported that administered PGEl inhibits insulin re- 
lease in dogs (12). No information is available on the effects of PG 
upon secretion or plasma levels of glucagon. In order to establish 
whether PG may influence the secretion of glucagon and to elucidate the 
role of PG in the release of insulin, the isolated intact rat pancreas 
was perfused in vitro with solutions containing varying concentrations -- 
of PGE2. The results of our studies indicate that PGE2 is a potent 
secretagogue of glucagon as well as of insulin release. 
MATERIALS AND METHODS 
Wale, albino Sprague-Dawley rats weighing 250-300 g were fed with 
Purina rat chow. Food was withdrawn 16-18 hours prior to the begin- 
ning of the experiments. The animals were anesthetized with sodium 
pentabarbital, 50 mg/kg body weight, injected intraperitoneally. The 
surgical technique employed for the removal of the pancreas’was a mod- 
ification of that described by Sussman et al. (13). The pancreas was 
dissected free from all surrounding structures; its connections to a 
short segment of the duodenum and its vasculature were left intact. 
All vessels not supplying the pancreas were ligated. The segment of 
the abdominal aorta from which the celiac and the superior mesenteric 
arteries originate was cannulated in a retrograde fashion and perfused 
with an oxygenated buffer medium. Another cannula was placed in the 
portal vein to collect the effluent from the pancreas. A third can- 
nula was inserted in the duodenum to ascertain the free flow of exo- 
crine pancreatic secretions and to relieve pressure in the pancreatic 
duct. To retain correct anatomical position of the vasculature, the 
pancreas was affixed on a small platform using ligatures which had 
been placed on the three cannulae. The surgical procedure was com- 
pleted within 60-80 minutes. During this period the pancreas was be- 
ing perfused either by the animal’s own circulation or by the oxygen- 
ated buffer medium so that the oxygen supply was adequate at all times. 
The isolated pancreas was suspended in a physiological buffer 
medium contained in a perfusion chamber. The chamber was placed in a 
perfusion apparatus which was a modification of that reported by 
Sussman et al. (13). The ambient temperature was 37O C. The system 
contained four independent perfusion channels which merged into a man- 
ifold to which the aortic cannula was connected. With the use of this 
manifold-regulated multichannel system, within a fraction of a second 
any one of the four perfusion solutions could be diverted to perfuse 
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the pancreas, while the remaining three solutions were being recircu- 
lated in an "idle"mode to permit continuous oxygenation and to pre- 
vent delays in changing buffer solutions. The flow rate was kept con- 
stant at 2.5 ml/min in all channels by using a multichannel roller 
pump. The aortic perfusion pressure was monitored at all times; the 
pressure ranged between 30-50 mm Hg and had a pulse amplitude of 2-4 
mm Hg. 
The artificial perfusion medium had the following composition 
(mmol/l): NaCl 118.5, KC1 3.5, MgSO4.7H20 1.0, KH2PO4 1.2, CaC12.2H20 
1.25, and NaHC03 24.9. Dextran, average mol. weight 70,000 (Pharma- 
cia), 40 g/l, and bovine serum albumin (Miles Labs.), 2 g/l, were add- 
ed to maintain a physiological oncotic pressure and to minimize ad- 
hesion of hormones to glassware. After equilibration with 95% 02 and 
5% CO2 the oxygen tension of the solution was around 400-450 mm Hg 
and the pH was 7.4. In all experiments the perfusion solutions con- 
tained 5.6 mM D-glucose at all times. 
L-arginine monohydrochloride (ICN) and PGE2 (Upjohn Co.) were 
dissolved directly in the perfusion medium. 
Following the attachment of the pancreas to the perfusion system, 
an equilibration period of 30 minutes preceded the experiments. All 
experiments were completed within 60-90 minutes. At the end of each 
experimental period the functional integrity of the pancreas was as- 
certained by assessing the glucagon and insulin secretory response to 
l-minute perfusions of 10 mM arginine. 
The portal venous effluent was collected in 12-60 second frac- 
tions. The samples were stored at -20' C until the time of hormone 
assays. 
Portal venous effluent levels of immunoreactive glucagon were 
measured by a "double-antibody" method using antiglucagon serum G9-I 
which has a negligible cross-reactivity with glucagon-like materials 
present in extracts of intestines (14). Immunoreactive insulin was 
determined by a modification of the method described by Morgan and 
Lazarow (15); rat insulin (Novo, Denmark) was used as standards. 
The statistical significance of differences between observed 
values was determined by paired t-test (16). 
RESULTS 
Solutions of PGE2 were prepared in seven different concentrations 
ranging from 1.1 x lo-9M to 1.8 x lo-5M. Each solution was adminis- 
tered to 4 pancreases over successive 2-minute periods, separated by 
lo-minute rest periods during which the organs were perfused with buf- 
fer alone. The results are shown in Fig. 1. At PGE2 concentrations 
of 2.8 x lo-8M or greater, the mean maximal effluent level of glucagon 
attained during the 5 minutes after the beginning of each perfusion 
period was significantly greater than the level observed during the 
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preceding basal period. Increases in insulin levels occurred consis- 
tently in response to PGE2 at 1.4 x 10m7M or greater. A dose-response 
relationship was observed for both islet hormones. 
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Fig. 1. Mean + S.E.M. maximal increments in 
portal venous effluent levels of glu- 
cagon and insulin induced by 2-minute 
perfusions of PGE2 in the presence of 
5.6 mM glucose. Asterisks denote that 
the increments were statistically sig- 
nificant (p<.O5-.OOl). 
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The rapidity of glucagon and insulin secretory res 
! 
onses was inves- 
tigated by.perfusing 6 pancreases with PGE2 1.4 x IO' M over 60 sec- 
onds and collecting 12-second effluent fractions over 180 seconds (Fig. 
2). The first significant increase above basal levels in glucagon 
occurred within 24 seconds at a time when no increases in insulin lev- 
els were discernable. If corrected for the 10 seconds which elapsed 
for the secretagogue to reach the pancreas, this response time would 
be reduced to 14 seconds. The first significant increment in insulin 
was observed at 48 seconds. The mean maximal responses in glucagon 
and insulin were 48 and 72 seconds, respectively. 
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Fig. 2. Mean _+ S.E.M. portal venous effluent levels 
of glucagon and insulin before, during and 
following 60-second perfusions with PGE2 in 
the presence of 5.6 mM glucose. The arrow- 
heads signify the first significant increases 
above basal levels. 
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The patterns of PG-induced secretion of glucagon and insulin were 
determined by perfusing 5 pancreases with 1.4 x 10q6M PGE2 over 10 
minutes (Fig. 3). The mean effluent glucagon increased from a basal 
value of 91 + 12 pg/ml to a maximal level of 838 + 148 pg/ml within 1 
minute. Mean glucagon decreased to around 300 pg/ml by the third min- 
ute and was sustained at this level until the termination of the per- 
fusion of PGE2. A similar biphasic release was observed also in insu- 
lin. The mean maximal level of 37 + 18 pU/ml was attained at 2 min- 
utes. The Phase I release was completed by the fourth minute. There- 
after insulin levels remained significantly elevated above the basal 
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Fig. 3. Mean + S.E.M. portal venous effluent levels 
of glucagon and insulin before and during lo- 
minute perfusions with 1.4 x 10m6M PGE2 in 
the presence of 5.6 mM glucose. 
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The effects of PG upon the release of pancreatic hormones in re- 
sponse to another secretagogue were examined. Each pancreas was per- 
fused with 10 mM solutions of arginine over two 15-minute periods. 
For 10 minutes preceding and during one of these periods of arginine 
administration the perfusate contained PGE2, 2.8 x lo-7M. The test 
periods were separated by 15-minute rest periods and were arranged 
randomly. Arginine evoked the expected biphasic increases in the lev- 
els of glucagon and insulin; Phase I release dissipated within 4-5 
minutes. Phase I and Phase II hormonal responses were computed as in- 
cremental areas under the response curve (Table 1). PGEI, augmented 
both phases of glucagon and of insulin release induced by arginine. 
Mean : S.E.M. incremental 
insulin to 15-minute 
Table 1 
response areas in glucagon and 
perfusioes of 10 mM arginine 
with and without 2.8 x 10-/M PGE2 (N=6) 
Arginine 
PGE2 + Arginine 
P< 
Glucagon, pg.min/ml 
Phase I Phase II 
(O-4 min) (4-15 min) 
1859 2957 
+ 427 _+ 675 
4312 7306 
2 930 k 1859 
0.05 0.05 
Insulin, pU.min/ml 
Phase I Phase II 
(O-4 min) (4-15 min) 
617 978 
2 76 + 123 
904 1415 
+ 102 2 160 
0.05 0.01 
DISCUSSION 
The results of our studies indicate that administered PGE2 is a 
potent secretagogue of glucagon as well as of insulin in the isolated 
rat pancreas. 
The physiological significance of these observations remains to 
be established. Karim et al. have reported that the concentration of 
PGE2 in the rat pancreas is 18.2 rig/g wet tissue (17). The lowest 
perfusate concentrations of PGE2 at which we have observed significant 
increases in glucagon and insulin release approach those tissue levels. 
These findings are consistent with the hypothesis that prostaglandin 
synthesis within the pancreas may be one of the mechanisms regulating 
the secretion of glucagon and insulin. 
As demonstrated in the studies reported here for arginine, the 
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secretion of islet hormones in response to a variety of stimuli is 
biphasic. The release of glucagon and insulin induced by administered 
PGE2 was also biphasic. Thus endogenous PG may play a role as med- 
iators of biphasic islet hormone release in response to certain stim- 
uli. 
PG-induced glucagon release preceded that of insulin. We have 
reported that such sequential release of glucagon and insulin occurs 
in response to a variety of stimuli common to both hormones (18). 
Glucagon stimulates insulin release when administered in pharmacolo- 
gical amounts (19). Thus prior release of glucagon observed in our 
studies may have a physiological significance in the secretion of 
insulin which follows. However, the analysis of our results failed 
to reveal any correlation between the dynamics or the magnitudes of 
glucagon release (18). Therefore, under the conditions which pre- 
vailed in our studies, the antecedent release of glucagon does not 
appear to be the principal mediator of insulin release. On the other 
hand, at times when both islet hormones are being secreted, a role 
for endogenous glucagon as a modifier of insulin release has not been 
ruled out. 
Among prostaglandins, PGEZ does not appear to be unique in stim- 
ulating the release of glucagon and insulin. Our preliminary studies 
indicate that PGEl and PGFza have similar effects on both islet hor- 
mones (20). The obversations made by others (3-5) on the stimulation 
of insulin release by PGEl are in support of our findings. 
In conclusion, prostaglandins may be involved in the regulation 
of secretion of glucagon and insulin and may mediate and/or modify 
the pancreatic islet hormone response to other secretagogues. 
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